Literature DB >> 16504816

Future directions in myoma research.

Pavna K Brahma1, Kristina M Martel, Gregory M Christman.   

Abstract

This article highlights our current knowledge of fibroids and addresses future directions for fibroid research and treatment over the next decade. The available data on cytogenetics are discussed, in addition to discoveries into signaling pathways and second messenger molecules in leiomyomas. Current medical management, surgical trends and the barriers to transition to minimally invasive procedures are summarized. Innovations in genetic diagnosis and interventional radiologic-aided therapies may revolutionize therapy for certain populations of patients who have fibroids. From tissue-specific medical management, to minimally invasive surgical techniques, to pharmacogenetics, the current directions of fibroid research are leading us to an exciting new frontier.

Entities:  

Mesh:

Year:  2006        PMID: 16504816     DOI: 10.1016/j.ogc.2005.12.011

Source DB:  PubMed          Journal:  Obstet Gynecol Clin North Am        ISSN: 0889-8545            Impact factor:   2.844


  13 in total

1.  An endocrine-disrupting chemical, fenvalerate, induces cell cycle progression and collagen type I expression in human uterine leiomyoma and myometrial cells.

Authors:  Xiaohua Gao; Linda Yu; Lysandra Castro; Alicia B Moore; Tonia Hermon; Carl Bortner; Maria Sifre; Darlene Dixon
Journal:  Toxicol Lett       Date:  2010-03-15       Impact factor: 4.372

Review 2.  Medical treatment of uterine leiomyoma.

Authors:  Mohamed Sabry; Ayman Al-Hendy
Journal:  Reprod Sci       Date:  2012-02-28       Impact factor: 3.060

Review 3.  Reproductive tract function and dysfunction in women.

Authors:  Angshumoy Roy; Martin M Matzuk
Journal:  Nat Rev Endocrinol       Date:  2011-05-24       Impact factor: 43.330

Review 4.  Tissue-specific stem cells in the myometrium and tumor-initiating cells in leiomyoma.

Authors:  Masanori Ono; Serdar E Bulun; Tetsuo Maruyama
Journal:  Biol Reprod       Date:  2014-11-05       Impact factor: 4.285

5.  Leiomyoma simultaneously impair endometrial BMP-2-mediated decidualization and anticoagulant expression through secretion of TGF-β3.

Authors:  Donna C Sinclair; Alex Mastroyannis; Hugh S Taylor
Journal:  J Clin Endocrinol Metab       Date:  2010-11-17       Impact factor: 5.958

6.  Association of germline mutations in the fumarate hydratase gene and uterine fibroids in women with hereditary leiomyomatosis and renal cell cancer.

Authors:  Laveta Stewart; Gladys M Glenn; Pamela Stratton; Alisa M Goldstein; Maria J Merino; Margaret A Tucker; W Marston Linehan; Jorge R Toro
Journal:  Arch Dermatol       Date:  2008-12

7.  Lipopolysaccharide activated TLR4/NF-κB signaling pathway of fibroblasts from uterine fibroids.

Authors:  Jing Guo; Lihua Zheng; Li Chen; Ning Luo; Weihong Yang; Xiaoyan Qu; Mingmin Liu; Zhongping Cheng
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

8.  Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas.

Authors:  Linda Yu; Katrin Saile; Carol D Swartz; Hong He; Xiaolin Zheng; Grace E Kissling; Xudong Di; Shantelle Lucas; Stanley J Robboy; Darlene Dixon
Journal:  Mol Med       Date:  2008 May-Jun       Impact factor: 6.354

9.  Innovative oral treatments of uterine leiomyoma.

Authors:  Mohamed Sabry; Ayman Al-Hendy
Journal:  Obstet Gynecol Int       Date:  2012-02-16

10.  Cost-effectiveness of magnetic resonance guided focused ultrasound for the treatment of uterine fibroids.

Authors:  Amy K O'Sullivan; David Thompson; Paula Chu; David W Lee; Elizabeth A Stewart; Milton C Weinstein
Journal:  Int J Technol Assess Health Care       Date:  2009-01       Impact factor: 2.188

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.